This specific species, Telmatosaurus transsylvanicus, has already proven to be a vital case study in this field. A separate, earlier study identified clear evidence of a tumor in a Telmatosaurus fossil, marking one of the earliest recorded instances of cancer in the fossil record. This evidence indicates that the evolutionary roots of cancer are deep, stretching back to a time when the world was dominated by reptilian giants. Understanding how these ancient animals lived with, resisted, or succumbed to such diseases could provide modern medicine with a roadmap for developing future treatments.
Senior author Justin Stebbing, a Professor of Biomedical Sciences at Anglia Ruskin University and a leading figure in the study, emphasizes the unique perspective that dinosaurs offer to the medical community. "Dinosaurs, as long-lived, large-bodied organisms, present a compelling case for investigating how species managed cancer susceptibility and resistance over millions of years," Professor Stebbing noted.
In the context of human health, the study of large-bodied animals is particularly relevant. In biology, a phenomenon known as Peto’s Paradox observes that at the species level, the incidence of cancer does not appear to correlate with the number of cells in an organism or its lifespan. One might expect that a massive dinosaur, with trillions more cells than a human and a lifespan that could span decades, would be statistically more likely to develop cancerous mutations. Yet, many of these ancient giants clearly possessed biological mechanisms that allowed them to reach maturity and thrive. Professor Stebbing’s research suggests that by unlocking the molecular secrets of dinosaur proteins, we may find the "switches" or "brakes" that these organisms used to suppress tumor growth.
The choice to focus on proteins rather than DNA is a strategic one, dictated by the laws of chemistry. "Proteins, particularly those found in calcified tissues like bone, are more stable than DNA and are less susceptible to degradation and contamination," Professor Stebbing explained. "This makes them ideal candidates for studying ancient diseases, including cancer, in paleontological specimens."
While DNA is often described as the "blueprint" of life, it is notoriously fragile, breaking down relatively quickly after an organism dies. Even under ideal conditions, the half-life of DNA is such that recovering usable genetic information from the age of the dinosaurs is currently beyond the reach of science. Proteins, however, are the "workhorses" of the cell. They are more durable and can become trapped within the mineral matrix of bone, acting as a molecular time capsule.
Professor Stebbing further elaborated on the distinction between looking at bones and looking at the chemistry within them. "Unlike skeletal structures alone, soft tissues contain proteins that provide molecular information that can reveal the underlying biological mechanisms of disease," he said. This molecular information can tell researchers about the immune responses of dinosaurs, their metabolic rates, and how their bodies reacted to cellular damage—data points that are invisible when looking at a standard X-ray or a reconstructed skeleton.
